FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocar
Go back to FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocar| Merck & Co. (NYSE: MRK) | Delayed: 149.10 -1.23 (0.82%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $150.33 | 52 Week High | $65.46 | |||
| Open | $148.41 | 52 Week Low | $47.97 | |||
| Day High | $149.52 | P/E | 101.43 | |||
| Day Low | $146.28 | EPS | $1.47 | |||
| Volume | 1,303,785 | |||||
